Recent Updates
Recently added Catalysts
DHR Positive Sentiment

Digital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment

Thursday, February 12, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: In a recent episode of Denatured, experts from Danaher Corporation discuss the impact of digital pathology and artificial intelligence on HER2 cancer treatment. Dr. Rob Monroe and Jennifer Fakish highlight how these technologies facilitate accurate measurement of HER2 levels, ensuring patients receive the most effective antibody-drug conjugate (ADC) treatments. The conversation underscores the advancements in oncology driven by innovative technologies.
Price reaction · baseline $219.98 (2026-02-11 close) · hit after-hours · 1 other DHR headline(s) in the window, move may be shared
day 0 close · peak
-2.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Digital pathology enhances accuracy in measuring HER2 levels.
  • AI technology improves patient access to effective ADC treatments.
  • Expert insights from leading professionals in oncology.

Full Press Release Details

> Listen on Spotify> Listen on Apple podcasts> Listen on Amazon Music
In this episode of Denatured, Jennifer C. Smith-Parker speaks with Dr. Rob Monroe, Vice President and Chief Scientific Officer of Oncology at Danaher Corporation and Chief Medical Officer at Leica Biosystems, and Jennifer Fakish, Vice President and Franchise Head of Oncology at Danaher Corporation. They offer expert insights on how digital pathology and artificial intelligence are making it much easier to accurately measure HER2 levels, meaning patients can get the most effective ADC treatments for their cancer.
Host
⁠Jennifer Smith-Parker⁠, Director of Insights, BioSpace
Guests
⁠Dr. Rob Monroe⁠, Vice President and Chief Scientific Officer, Oncology, Danaher Corporation; Chief Medical Officer, Leica Biosystems
⁠Jennifer Faikish⁠, Vice President and Franchise Head, Oncology, Danaher Corporation
Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Frequently Asked Questions

What is the focus of the Denatured podcast episode?

The episode discusses digital pathology and AI's role in HER2 cancer treatment.

Who are the guests featured in the episode?

Dr. Rob Monroe and Jennifer Fakish from Danaher Corporation are featured.

How does digital pathology benefit cancer treatment?

It enhances the accuracy of measuring HER2 levels for effective treatments.

What role does AI play in oncology according to the episode?

AI improves patient access to effective antibody-drug conjugate treatments.

ShareAdd on Google
Tags: DHR Danaher Corporation digital pathology AI HER2 ADC treatments
Last updated: Feb 12, 2026

Biotech snapshot

Cash runway
$4348M liquidity · $0M/mo burn
Low dilution risk